On Wednesday, Following Stocks were among the “Top Losers” of U.S. Stock Market: Willbros Group, (NYSE:WG), Celladon Corporation, (NASDAQ:CLDN), OvaScience, (NASDAQ:OVAS), RADA Electronic Industries, (NASDAQ:RADA)
Willbros Group, (NYSE:WG), with shares declined -10.57%, closed at $2.96.
Celladon Corporation, (NASDAQ:CLDN), with shares dropped -10.40%, settled at $16.97.
OvaScience, (NASDAQ:OVAS), with shares dipped -10.31%, and closed at $31.15.
RADA Electronic Industries, (NASDAQ:RADA), plummeted -10%, and closed at $2.61.
Latest NEWS regarding these Stocks are depicted underneath:
Willbros Group Inc. (NYSE:WG)
Willbros Group Inc. (WG), declared results from ongoing operations for the fourth quarter and full year 2014. The Corporation stated a net loss from ongoing operations in the fourth quarter of $36.0 million, or $0.72 per share, on proceed of $450.7 million, contrast to a net profit of $12.8 million, or $0.27 per share, on proceed of $505.1 million for the same period in 2013. The fourth quarter results comprised of a $14.2 million, or $0.28 per share, non-cash debt extinguishment charge, and other charges of about $7.0 million, or $0.14 per share, associated with the investigation behind the deterioration of certain construction projects and employee severance costs associated with headcount reductions. For the full year 2014, the Corporation stated a net loss from ongoing operations attributable to Willbros Group, Inc. of $79.8 million, or $1.62 per share, on proceed of $2.0 billion, contrast to a net loss of $15.9 million, or $0.32 per share, on proceed of $1.9 billion in 2013, which comprised of a non-cash debt extinguishment charge of $11.6 million, or $0.23 per share. Fiscal 2014 results comprised of non-cash debt extinguishment charges of $15.2 million, or $0.31 per share, primarily associated with the refinancing of our credit facilities. The fourth quarter generated an operating loss of $15.1 million contrast to operating revenue of $15.4 million in 2013, and the full year 2014 generated an operating loss of $2.8 million contrast to operating revenue of $31.5 million in 2013.
John T. McNabb, II, Chairman and Chief Executive Officer, commented, “Our 2014 results were influenced by challenging market conditions, losses in the regional delivery model in our Oil & Gas segment and costs we incurred to right-size the Oil & Gas segment.
Willbros Group, Inc., together with its auxiliaries, operates as an energy infrastructure contractor serving the oil, gas, refining, petrochemical, and power industries in the United States and internationally. It provides engineering, procurement, and construction (EPC); and turnarounds, maintenance, facilities development, and operations services.
Celladon Corporation (NASDAQ:CLDN)
Formerly on March 24, Celladon Corporation (CLDN), declared that they have signed a Development, Manufacturing and Supply Contract following which, if supported by forthcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.
The contract follows an earlier letter contract concerning the initial process transfer of MYDICAR and pre-validation studies, which was signed in December 2014. The new contract continues the work necessary for Novasep to achieve GMP production of MYDICAR drug substance.
“We are very happy to have the option to partner with Novasep to prepare for and commence commercial manufacturing of MYDICAR drug substance,” said Dr. Krisztina Zsebo, CEO of Celladon. “Novasep has demonstrated technical excellence and a real commitment to assisting advance the MYDICAR program.”
Celladon Corporation, a clinical-stage biotechnology corporation, focuses on developing cardiovascular gene therapy and calcium dysregulation. The corporations lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, in addition to to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure.
OvaScience, Inc. (NASDAQ:OVAS)
OvaScience, Inc. (OVAS), dropped down Wednesday. According to Zacks Equity Research, OvaScience has seen 5 negative revisions in the past few weeks and its current year consensus loss estimate has widened over the last 30 days. This suggests there may be more trouble down the road. OVAS presently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
OvaScience, Inc., a life science corporation, engages in the discovery, development, and commercialization of new treatments for infertility. The corporation’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries.
RADA Electronic Industries Ltd. (NASDAQ:RADA)
RADA Electronic Industries Ltd. (RADA), declared that it has signed a planned teaming contract with DRS Technologies, Inc. to bring RADA’s tactical active electronically scanned array (AESA) radar technology into the North American market.
Under this contract, DRS will market, sell, produce and support tactical AESA radars as part of its tactical radar portfolio. The combination of RADA’s technology together with DRS market presence, customer awareness, engineering, and production capabilities is predictable to produce noteworthy interest in the North American defense industry market.
RADA Electronic Industries Ltd., a defense electronics contractor, is engaged in the development, manufacture, and sale of defense electronics to various air forces and companies worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
